Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Occurrence of erythema multiforme following COVID-19 vaccination: a review

  • Marzieh Yousefian (Department of Oral and Maxillofacial Medicine, School of Dentistry, Alborz University of Medical Sciences) ;
  • Alireza Khadivi (School of Dentistry, Alborz University of Medical Sciences)
  • Received : 2022.11.27
  • Accepted : 2023.02.02
  • Published : 2023.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The fast development of vaccines against the novel coronavirus disease is among the most critical steps taken to control this potentially fatal viral disease. Like other vaccines, the coronavirus disease 2019 (COVID-19) vaccines can also cause unwanted reactions. Erythema multiforme (EM) is among the oral mucocutaneous side effects of COVID-19 vaccines. This study aimed to comprehensively review the reported cases of EM since the global onset of COVID-19 vaccination. Data from 31 relevant studies regarding the type and dose of COVID-19 vaccines administered, time of initiation of symptoms, age, and gender of patients, site of involvement, patients' medical history, and treatment options were extracted. In total, 90 patients were identified with EM as a side effect of COVID-19 vaccination across studies. EM had the highest frequency after receiving the first dose of mRNA vaccines in older individuals. The first symptoms of EM appeared in less than 3 days in 45% and after 3 days in 55% of patients. EM is not a common side effect of COVID-19 vaccination, and fear of its occurrence should not impede vaccination.

Keywords

References

  1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
  2. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 020;579:265-9.
  3. Nakamichi K, Shen JZ, Lee CS, et al. Hospitalization and mortality associated with SARS-CoV-2 viral clades in COVID-19. Sci Rep 2021;11:4802.
  4. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep 2021;70:46-51.
  5. Craven J. COVID-19 vaccine tracker. Rockville (MD): Regulatory Affairs Professionals Society; 2021.
  6. Chung EH. Vaccine allergies. Clin Exp Vaccine Res 2014;3:50-7.
  7. Rosenblatt AE, Stein SL. Cutaneous reactions to vaccinations. Clin Dermatol 2015;33:327-32.
  8. Bujan Bonino C, Moreiras Arias N, Lopez-Pardo Rico M, et al. Atypical erythema multiforme related to BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Int J Dermatol 2021;60:e466-7.
  9. Su JR, Haber P, Ng CS, et al. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. Vaccine 2020;38:1746-52.
  10. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983;8:763-75.
  11. Ayangco L, Rogers RS 3rd. Oral manifestations of erythema multiforme. Dermatol Clin 2003;21:195-205.
  12. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000;83:347-52.
  13. Kennett S. Erythema multiforme affecting the oral cavity. Oral Surg Oral Med Oral Pathol 1968;25:366-73.
  14. Rongioletti F, Ferreli C, Sena P, Caputo V, Atzori L. Clinicopathologic correlations of COVID-19-related cutaneous manifestations with special emphasis on histopathologic patterns. Clin Dermatol 2021;39:149-62.
  15. Wunderlich K, Dirschka T. Erythema multiforme following COVID-19 vaccination (BNT162b2). Hautarzt 2022;73:68-70.
  16. Lavery MJ, Nawimana S, Parslew R, Stewart L. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Clin Exp Dermatol 2021;46:1325-7.
  17. Sechi A, Pierobon E, Pezzolo E, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol 2022;47:437-40.
  18. de Las Vecillas L, Lopez J, Morchon E, Rodriguez F, Drake M, Martino M. Viral-like reaction or hypersensitivity?: erythema multiforme minor reaction and moderate eosinophilia after the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 vaccine. J Investig Allergol Clin Immunol 2021;32:77-8.
  19. Kothari RS, Subramani D, Asnani DR, Raman A, Deora MS, Gupta A. Erythema multiforme after Covishield/ChAdOx1 vaccination. Dermatol Ther 2022;35:e15289.
  20. Erythema multiforme after SARS-CoV-2 messenger RNA vaccination. QJM 2022;115:37-8.
  21. Gambichler T, Scholl L, Dickel H, Ocker L, Stranzenbach R. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol 2021;35:e415-6.
  22. Kim MJ, Kim JW, Kim MS, Choi SY, Na JI. Generalized erythema multiforme-like skin rash following the first dose of COVID-19 vaccine (Pfizer-BioNTech). J Eur Acad Dermatol Venereol 2022;36:e98-100.
  23. Scharf C, Di Brizzi EV, Pellerone S, Liguori M, Giorgio CM, Argenziano G. Nevocentric erythema multiforme after SARS-COV-2 vaccine. J Eur Acad Dermatol Venereol 2022;36:e30-2.
  24. Lopes NT, Pinilla CE, Gerbase AC. Erythema multiforme after CoronaVac vaccination. J Eur Acad Dermatol Venereol 2021;35:e717-9.
  25. Karatas E, Nazim A, Patel P, et al. Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: a case series. JAAD Case Rep 2023;32:55-8.
  26. Iwasawa O, Kamiya K, Komine M, Ohtsuki M. Case of atypical erythema multiforme following coronavirus disease 2019 vaccination. J Dermatol 2022;49:e113-4.
  27. Saibene AM, Alliata A, Cozzi AT, et al. Erythema multiforme major following SARS-CoV-2 vaccine. Clin Case Rep 2021;9:e04947.
  28. Ibrahim MM. Erythema multiforme after Pfizer-BioNTech COVID-19 vaccination in Iraqi patient. Med Leg Update 2022;22:67-9.
  29. Lefeuvre M, Kerneuzet I, Darrieux L, Safa G. Multisystem inflammatory syndrome with erythema multiforme-like rash in an adult after mRNA COVID-19 vaccination. Ann Dermatol Venereol 2022;149:211-3.
  30. Borg L, Mercieca L, Mintoff D, et al. Pfizer-BioNTech SARSCoV-2 mRNA vaccine-associated erythema multiforme. J Eur Acad Dermatol Venereol 2022;36:e22-4.
  31. Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis 2022;10:265-71.
  32. Wang C, Rademaker M, Tate B, Baker C, Foley P. SARSCoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: recommendations from the Australasian Medical Dermatology Group. Australas J Dermatol 2021;62:151-6.
  33. Katayama S, Ota M. Erythema multiforme after BNT162b2 vaccination. Intern Med 2022;61:1929.
  34. Petruzzi M, Galleggiante S, Messina S, Della Vella F. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases. BMC Oral Health 2022;22:90.
  35. Gimeno Castillo J, Roses Gibert P, Romero Abrio C, et al. Erythema multiforme after the third dose of mRNA-1273. Dermatol Ther 2022;35:e15497.
  36. Haranaka M, Baber J, Ogama Y, et al. A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nat Commun 2021;12:7105.
  37. Majenka P, Naoum C, Hartmann M. Multiform erythema after COVID-19 mRNA vaccination. Dtsch Arztebl Int 2021;118:690.
  38. Niebel D, Wilhelmi J, De Vos L, et al. Annular plaques mimicking Rowell's syndrome in the course of coronavirus disease 2019 mRNA vaccines: an overlooked phenomenon? J Dermatol 2022;49:151-6.
  39. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021;85:46-55.
  40. Tan SW, Tam YC, Pang SM. Cutaneous reactions to COVID-19 vaccines: a review. JAAD Int 2022;7:178-86.
  41. Freeman EE, Sun Q, McMahon DE, et al. Skin reactions to COVID-19 vaccines: an American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type. J Am Acad Dermatol 2022;86:e165-7.
  42. Pourani MR, Shahidi Dadras M, Salari M, Diab R, Namazi N, Abdollahimajd F. Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients. Dermatol Ther 2022;35:e15223.
  43. Lee DS, Kim JW, Lee KL, Jung YJ, Kang HW. Adverse events following COVID-19 vaccination in South Korea between February 28 and August 21, 2021: a nationwide observational study. Int J Infect Dis 2022;118:173-82.
  44. McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: a registry-based study. J Am Acad Dermatol 2022;86:113-21.
  45. Larson V, Seidenberg R, Caplan A, Brinster NK, Meehan SA, Kim RH. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol 2022;49:34-41.
  46. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:803-12.
  47. Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, et al. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol 2020;45:892-5.
  48. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16:626-38.
  49. Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology (Bethesda) 2015;30:408-16.
  50. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males: implications for vaccine efficacy. Curr Opin Physiol 2018;6:16-20.
  51. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol 2019;41:239-49.
  52. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 2017;33:577-99.
  53. Robinson LB, Fu X, Hashimoto D, et al. Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines. JAMA Dermatol 2021;157:1000-2.
  54. Studdiford J, Oppenheim L, McCann E, Altshuler M. Erythema multiforme after meningitis vaccine: patient safety concerns with repeat immunization. Pharmacotherapy 2006;26:1658-61.
  55. Perez-Carmona L, Aguayo-Leiva I, Gonzalez-Garcia C, Jaen-Olasolo P. The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration. Dermatology 2010;221:197-200.
  56. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021;325:780-1.
  57. Klimek L, Novak N, Hamelmann E, et al. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). Allergo J Int 2021;30:51-5.
  58. Kelso JM. Anaphylactic reactions to novel mRNA SARSCoV-2/COVID-19 vaccines. Vaccine 2021;39:865-7.
  59. Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol? Allergy 2021;76:1617-8.
  60. Frank A, Radparvar S, Manasia A, Bassily-Marcus A, KohliSeth R. Prolonged anaphylaxis to Pfizer coronavirus disease 2019 vaccine: a case report and mechanism of action. Crit Care Explor 2021;3:e0397.
  61. Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth 2021;126:e106-8.
  62. Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract 2021;9:1423-37.
  63. Kounis NG, Koniari I, de Gregorio C, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines (Basel) 2021;9:221.
  64. Azenha Rama T, Alvarez-Twose I. Delving into COVID-19 vaccination-induced anaphylaxis: are mRNA vaccines safe in mast cell disorders? J Investig Allergol Clin Immunol 2021;31:193-5.
  65. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39-51.
  66. Ostergaard SD, Schmidt M, Horvath-Puho E, Thomsen RW, Sorensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet 2021;397:1441-3.
  67. Chapman RS, Forsyth A, MacQueen A. Erythema multiforme in association with active ulcerative colitis and Crohn's disease. Dermatologica 1977;154:32-8.
  68. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol 2009;4:417-34.
  69. Duvic M, Reisner EG, Dawson DV, Ciftan E. HLA-B15 association with erythema multiforme. J Am Acad Dermatol 1983;8:493-6.
  70. Middleton D, Hutchison TH, Lynd J. HLA antigen frequency in erythema multiforme and in recurrent herpes simplex. Tissue Antigens 1983;21:264-7.
  71. Kampgen E, Burg G, Wank R. Association of herpes simplex virus-induced erythema multiforme with the human leukocyte antigen DQw3. Arch Dermatol 1988;124:1372-5.
  72. Lepage V, Douay C, Mallet C, et al. Erythema multiforme is associated to HLA-Aw33 and DRw53. Tissue Antigens 1988;32:170-5.
  73. Simon M Jr, Fuchs C. HLA pattern in patients with post-herpetic erythema exsudativum multiforme. Z Hautkr 1990;65:303-4.
  74. Khalil I, Lepage V, Douay C, et al. HLA DQB1*0301 allele is involved in the susceptibility to erythema multiforme. J Invest Dermatol 1991;97:697-700.
  75. Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J 2018;24:13030/qt7qn5268s.
  76. Bean SF, Quezada RK. Recurrent oral erythema multiforme: clinical experience with 11 patients. JAMA 1983;249:2810-2.
  77. Shklar G, McCarthy PL. Oral manifestations of erythema multiforme in children. Oral Surg Oral Med Oral Pathol 1966;21:713-23.
  78. Lozada-Nur F, Gorsky M, Silverman S Jr. Oral erythema multiforme: clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol 1989;67:36-40.
  79. Lozada F, Silverman S Jr. Erythema multiforme: clinical characteristics and natural history in fifty patients. Oral Surg Oral Med Oral Pathol 1978;46:628-36.
  80. Kelso JM, Greenhawt MJ, Li JT, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012;130:25-43.
  81. Lamoreux MR, Sternbach MR, Hsu WT. Erythema multiforme. Am Fam Physician 2006;74:1883-8.